Robert B. Parker

Robert B. Parker

Auto-generated profile, based on publicly available information

Robert B. Parker

Department of Clinical Pharmacy and Translational Science University of Tennessee Health Science Center College of Pharmacy Memphis Tennessee USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2014 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
RPRobert B. Parker
Robert B. Parker
ZHZhe-Yi Hu
Zhe-Yi Hu
BMBernd Meibohm
Bernd Meibohm
SLS. Casey Laizure
S. Casey Laizure

1 July 2011 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
RPRobert B. Parker
Robert B. Parker
JSJudith E. Soberman
Judith E. Soberman

30 September 2013 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
RPRobert B. Parker
Robert B. Parker
VEVicki Ellingrod
Vicki Ellingrod
JDJoseph T. DiPiro
Joseph T. DiPiro
JBJerry L. Bauman
Jerry L. Bauman
RBRobert A. Blouin
Robert A. Blouin
LWLynda S. Welage
Lynda S. Welage

8 August 2014 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
ZHZhe-Yi Hu
Zhe-Yi Hu
AEAndrea N. Edginton
Andrea N. Edginton
SLS. Casey Laizure
S. Casey Laizure
RPRobert B. Parker
Robert B. Parker

18 October 2022 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
SLS. Casey Laizure
S. Casey Laizure
FCFeng Chen
Feng Chen
JFJulie Farrar
Julie Farrar
DADina Ali
Dina Ali
BYBing Yang
Bing Yang
RPRobert B. Parker
Robert B. Parker

15 May 2019 in Xenobiotica
Verified
Journal Article
Closed access
SLS. Casey Laizure
S. Casey Laizure
ZHZhe-Yi Hu
Zhe-Yi Hu
PPPhilip M. Potter
Philip M. Potter
RPRobert B. Parker
Robert B. Parker
1. Clopidogrel is widely prescribed in patients with cardiovascular disease. Most research has focused on the role of hepatic CYP450 metabolism as the primary source of response variability despite 85-90% of clopidogrel being hydrolyzed by human carboxylesterase-1 (CES1). 2. The purpose of this study is to determine the effects of the known CES1 inhibitor alcohol on clopidogrel metabolism: (1) in vitro in human recombinant CES1 and human liver S9 fractions (HLS9), and (2) in a plasma carboxylesterase deficient mouse (Es1e ) strain administered 25 mg/kg oral clopidogrel alone and with 3 g/kg alcohol. 3. Alcohol significantly inhibited the hydrolysis of clopidogrel (IC50 161 mM) and 2-oxo-clopidogrel (IC50 6 mM). In HLS9, alcohol treatment formed ethylated metabolites via transesterification and an increased formation of the H4 active metabolite. These results were replicated in Es1e mice as alcohol increased clopidogrel (91%) and H4 (22%) AUC and reduced formation of the clopidogrel (48%) and 2-oxo-clopidogrel (42%) carboxylate metabolites. 4. Clopidogrel metabolism is highly sensitive to alterations in CES1 activity. The Es1e mouse may represent a suitable model of human CES1 drug metabolism that can be used to rapidly assess how alterations in CES1 function impact the disposition of the substrate drugs.